IADR Abstract Archives
Anti-RANKL Antibody Administration Suppresses Bone Destruction Induced by LPS in Mice
Objectives: Oral self-care is often difficult for handicapped individuals, increasing the risk of tooth loss from inflammatory alveolar-bone destruction induced by periodontitis. To examine possible treatment methods for periodontal disease, we examined the effects of two different types of anti-bone-resorptive drugs, an anti-RANKL antibody and bisphosphonate (zoledronate), on inflammatory bone destruction induced by the bacterial constituent LPS.
Methods: LPS with or without these drugs embedded using collagen gel was injected into the calvaria area of mice. After 5 days, calvaria were extracted and subjected to TRAP staining to detect osteoclasts, as well as micro-computed tomography analysis to evaluate bone resorption.
Results: Increased bone resorption and osteoclast numbers were observed on calvaria samples from mice that received LPS alone. However, when the anti-RANKL antibody or zoledronate was included, those were suppressed. On the other hand, when the same experiment was performed with mouse femurs, no significant effects by LPS or the drugs were observed.
Conclusions: These results suggest that an anti-RANKL antibody and zoledronate may be useful for treatment of inflammatory bone destruction induced by bacterial infection, including periodontitis.
Methods: LPS with or without these drugs embedded using collagen gel was injected into the calvaria area of mice. After 5 days, calvaria were extracted and subjected to TRAP staining to detect osteoclasts, as well as micro-computed tomography analysis to evaluate bone resorption.
Results: Increased bone resorption and osteoclast numbers were observed on calvaria samples from mice that received LPS alone. However, when the anti-RANKL antibody or zoledronate was included, those were suppressed. On the other hand, when the same experiment was performed with mouse femurs, no significant effects by LPS or the drugs were observed.
Conclusions: These results suggest that an anti-RANKL antibody and zoledronate may be useful for treatment of inflammatory bone destruction induced by bacterial infection, including periodontitis.